INTRODUCTION
The systematic development and clinical application of genetically modified T cells is an example of how academic scientists working at non-profit medical centers are generating a new class of therapeutics. In this context, gene therapy has been used to overcome one of the major barriers to Tcell therapy of cancer, namely tolerance to desired target tumor-associated antigens (TAAs). This was achieved by the introduction of a chimeric antigen receptor (CAR) to redirect T-cell specificity to a TAA expressed on the cell surface. The prototypical CAR uses a mouse monoclonal antibody (mAb) that docks with a designated TAA and this binding event is reproduced by the CAR to trigger desired T-cell activation and effector functions. Multiple early phase clinical trials are now underway or have been completed to evaluate the safety and feasibility of adoptive transfer of CAR + T cells (Table 1) . These pilot studies have revealed challenges in achieving reproducible therapeutic successes which may be solved by (a) reprogramming the T cells themselves for improved replicative potential, effector function, and in vivo persistence, (b) manipulating the recipient to improve TAA expression and survival of infused T cells, and (c) adapting the gene therapy platform to deliver (i)
CARs capable of initiating an antigen-dependent fully-competent activation signal, and (ii) transgenes to improve safety, persistence, homing, and effector functions within the tumor microenvironment.
Academic investigators who work to both develop and deliver investigational biological agents such as CAR + T cells are poised to further tighten the pace of discovery between the bench and the bedside to improve the therapeutic potential of genetically modified T cells with redirected specificity.
This review builds upon recent articles that describe the immunobiology of CAR + T cells ( Table 2) and we highlight how the CAR technology has been adapted to meet the challenges of infusing genetically modified T cells in medically fragile patients with aggressive malignancies and what new directions the field will need to embrace to undertake multi-center trials to prove their therapeutic efficacy.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From CD28, CD134, CD137, Lck, ICOS and DAP10. 6, [12] [13] [14] A listing of such CARs is provided by Berry et al., 15 and Sadelain et al., 16 . While the optimal CAR design remains to be determined, at present it is believed that the 1 st generation technology, in which a CAR signals solely through ITAM domains on CD3-ζ, is insufficient to sustain in vivo persistence of T cells. 17 This is supported by early clinical data which demonstrate that CD19-specific, 18 CD20-specific, 19 GD 2 -specific (not EBV-bi-specific), 20 and L1-CAM (Cell Adhesion Molecule)-specific 21 T cells had apparently short-lived persistence in peripheral blood. The decision regarding which 2 nd or even 3 rd generation CAR design to employ in clinical trials is predicated on the ability of a CAR to activate T cells for desired T-cell effector function, which at a minimum includes CAR-dependent killing. However, it is possible that next generation
CARs can be engineered to provide a supra-physiologic activation signal which may be detrimental to continued T-cell survival and perhaps even the well-being of the recipient.
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Modifying the CAR to achieve a fully competent activation signal and reduce immunogenicity
The inclusion of one or more T-cell co-stimulatory molecules within the CAR endodomain is in response to the appreciation that genetically modified and ex vivo propagated T cells may have down regulated expression of desired endogenous co-stimulatory molecules (e.g. CD28) or that the ligands for these receptors may be missing on tumor targets (e.g. absence of CD80/CD86 on blasts from Blineage acute lymphoblastic leukemia). By way of example, chimeric CD28 and CD3-ζ, 17 ,23 CD137
and CD3-ζ, 13 ,24 or CD134 and CD3-ζ, 25, 26 have been incorporated into the design of 2 nd generation
CARs with the result that these CARs with multiple chimeric signaling motifs exhibited effector function stemming from a both a primary signal (e.g. killing) and co-stimulatory signal (e.g. IL-2 production) after an extracellular recognition event. However, a benefit for using human or humanized scFv regions is yet to be established in the clinical setting.
Imaging CAR + T cells by positron emission tomography
The ability to genetically modify T cells to redirect specificity provides investigators with a platform to express other transgenes such as for non-invasive imaging. Such temporal-spatial imaging is desired as a surrogate marker for a CAR-mediated anti-tumor effect and to serially determine number and localization of infused T cells. One imaging transgene co-expressed with CAR is thymidine kinase (TK) and associated mutants from herpes simplex virus (HSV)-1 36 which can be used to ability to exert a therapeutic effect. 20 Self-inactivating lentiviral vectors (Figure 3) (Figure 3) . 50, 55, [57] [58] [59] [60] [61] [62] [63] We have shown that the SB system can be used to introduce CAR and other transgenes into human T cells with an approximately 60-fold improved integration efficiency compared with electro-transfer of DNA transposon plasmid without transposase 53 and this provided the impetus to adapt the SB system for use in clinical trials. 64 Following electroporation, T-cell numbers from peripheral and umbilical cord blood can be rapidly increased in a CAR-dependent manner by recursive culture on γ-irradiated artificial antigen presenting cells (aAPC) achieving clinically sufficient numbers of cells for infusion within three to four weeks after electroporation (Figure 2) . Given that T cells transduced with γ-retrovirus are typically cultured with OKT3 and IL-2 for about three weeks prior to infusion, the use of the SB system with aAPC does not appear to greatly lengthen the ex vivo culturing process. clinical trial infusing tumor-infiltrating lymphocytes (TIL) genetically modified to constitutively secrete IL-2, the persistence of the adoptively transferred T cells was not improved compared to genetically unmodified TIL. 90 As constitutive expression of cytokines and/or cytokine receptors is tested in early clinical trials, investigators will need to consider co-expressing transgenes for conditional ablation of
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From these genetically modified T cells to guard against aberrant proliferation as un-opposed cytokine signaling may lead to aberrant T-cell growth. 88, 91 The type of T cell into which the CAR is introduced may also impact persistence after adoptive immunotherapy. This has been demonstrated in the monkey by infusing autologous pre-selected central memory T cells which despite ex vivo numeric expansion retained superior in vivo persistence compared with adoptive transfer of differentiated effector T cells. 92 These observations have been expanded upon by Hinrichs et al. who showed that an infusion of naïve murine T cells was associated with improved T-cell persistence. 93 These animal observations are likely to influence the design of trials infusing genetically modified T cells as investigators seek to introduce CARs into T cells that preserve the functional capacity of central memory or naïve T cells.
(2) Homing
To act on and within the tumor, genetically modified T cells must home to the site(s) of malignancy. Table 1 ) and systematic approaches to enabling infused T cells to effectively operate within a tumor microenvironment will be needed to reliably eliminate large tumor masses.
Reprogramming T cells
The ex vivo gene transfer and propagation ( . 41 However, the in vitro culturing process can also be adapted to modify T cells for desired effector function by the selective addition of a subset of soluble cytokines, e.g. that bind via common γ chain receptor, to the culture media during ex vivo culture. 101, 102 In addition, to help maintain a desired T-cell phenotype after gene transfer, investigators have provided co-stimulatory signals by the addition of CD28-specific mAb in addition to OKT3, often using beads conjugated to these mAbs. 
Safety of T cells expressing CAR
There are four levels of concern associated with the infusion of genetically modified T cells. The first is whether the introduced genetic material can lead to genotoxicity. This remains a theoretical concern for genetically modified T cells, in contrast to HSC. 124 The stable expression of CAR requires the introduction of a promoter and the transgene cDNA which raises the possibility of insertional mutagenesis. However, to date, there have been no genotoxic events associated with serious adverse events attributed to genetically modified T cells that have been transduced by recombinant virus or electroporated to introduce DNA plasmid. 125 The risk for insertional mutagenesis can be alleviated by the electro-transfer of in vitro transcribed mRNA coding for a CAR. Regarding the risks of transposition, a review has been published discussing the risks and benefits of the SB system for clinical application which addresses the low potential for genotoxicity. 127 For additional reviews on insertional mutagenesis in genetically modified T cells please refer to Table 2 . A second area of concern is whether the CAR can exhibits Furthermore, evidence appears to indicate that low-level expression of ERBB2 on normal lung cells may be associated with the sudden death of a patient at the NCI who received autologous HER2-specific T cells expressing a 3 rd generation CAR along with IL2. 22 The risks versus benefits must be calculated for a given patient and a given CAR on case-by-case basis.
For 
132-134 However, the degree of immunosuppression induced in the recipient and level of transgene expression likely determine the immunogenicity of the genetically modified cell. 135 There are potentially lessimmunogenic approaches to rendering T cells sensitive to conditional ablation such as expressing a mutant of human thymidinylate kinase 136 as well as activating Fas and inducible caspase 9 using a commercial dimerizing agent, which is currently in a clinical trial and has been successfully coexpressed with CAR without impairing its function. 137, 138 Furthermore, CD20 has been introduced as a non-immunogenic suicide mechanism as CD20 + T cells could be eliminated by rituximab.
139,140

Combining CAR + T cells with other immune-based therapies
The 
Regulatory barriers
The safety of the research participants in trials infusing CAR + T cells is of paramount importance. To maintain the well-being of patients multiple institutional and federal administrative layers of checks and balances have been developed. Thus, the trial's principal investigator and team not only need to develop the infrastructure to support infusing genetically modified T cells, but are required to also
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From obtain approvals from institutional review committees (IRB and IBC) as well as federal regulatory authorities (NIH-OBA and FDA). Further, the cGMP process itself contains checks and balances, as the manufacturing personnel are separate from the quality control program which in turn is separate from the quality assurance team. These processes have emerged to prevent serious adverse events from faults in production of genetically modified T cells. Working within this governance structure takes specialized expertise and consumes time and funding as large documents and copious data are prepared and reviewed. If CAR + T cells are to enter the mainstream of clinical practice, the regulatory processes will need to adapt so that multi-institution trials can be undertaken by academic centers.
CONCLUSIONS
The decision to infuse CAR + T cells is undertaken at the programmatic level as well as at the bedside. Currently, such genetically modified T cells are primarily infused in patients with aggressive malignancies who have received multiple prior therapies, although some pilot trials are investigating infusing CAR + T cells in patients with minimal residual disease and to prevent relapse in patients at high risk for disease progression. The risk of adoptively transferring genetically modified T cells is justified in these clinical scenarios as the underlying malignancy is considered resistant to conventional therapies. Thus, tolerance by regulators and administrative authorities is needed and appreciated regarding the expected toxicities that are likely to occur as new therapeutic approaches are evaluated in early-phase trials enrolling medically fragile patients. Investigator-initiated trials must balance the risks versus benefits, but the pace of genetic therapies needs to accelerate. 143, 144 One reason for the slow implementation of human studies using genetically modified T cells is that the design and activation of trials to infuse genetically modified T cells with redirected specificity has been expensive, but economies of scale and improvements in cGMP are rapidly driving down the associated costs. This is apparent from an application to the FDA for viral-specific T cells 145 to achieve orphan-drug status and their cost compares favorably with current anti-viral medications.
Indeed, if one considers genetically modified T cells as "drugs", the costs associated with their generation and delivery compares favorably with other biologic therapies such as mAbs and HSCT.
Scientists working with CAR + T cells benefit from being able to develop and infuse designer "drugs" that are personalized to the patient's needs and can be manufactured to clinical-standards on academic campuses to treat orphan diseases free of the encumbrances associated with manufacturing concerns that generate drugs for profit. This ability to apply cell therapy makes the science of CAR + T cells compelling not just for redirecting T-cell specificity, but establishes a framework for how non-profit academic centers can organize their laboratories and resources to operate for all intents and purposes as biotechnology companies to generate a clinical product.
Clinical translation of CAR + T cells is promising given the clinical responses described in early phase trials ( For 
